ORLANDO -- For triple-class exposed relapsed or refractory multiple myeloma with extramedullary disease (EMD), a combination ...
Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall response rate(ORR) in this subgroup of patients; 80% ORR ...
The last bit of momentum for Broadcom is the sector-wide momentum behind custom silicon. Industry reporting continues to point to Broadcom as the go-to partner for hyperscaler accelerators and AI ASIC ...
The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback